vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and BYLINE BANCORP, INC. (BY). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $83.5M, roughly 1.3× BillionToOne, Inc.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 6.8%, a 26.6% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 9.0%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
BLLN vs BY — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $112.4M |
| Net Profit | $5.7M | $37.6M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 33.4% |
| Revenue YoY | 117.4% | 9.0% |
| Net Profit YoY | 138.3% | 33.0% |
| EPS (diluted) | $0.10 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $112.4M | ||
| Q4 25 | — | $117.0M | ||
| Q3 25 | $83.5M | $115.7M | ||
| Q2 25 | — | $110.5M | ||
| Q1 25 | — | $103.1M | ||
| Q4 24 | $45.1M | $104.7M | ||
| Q3 24 | $38.4M | $101.8M | ||
| Q2 24 | — | $99.4M |
| Q1 26 | — | $37.6M | ||
| Q4 25 | — | $34.5M | ||
| Q3 25 | $5.7M | $37.2M | ||
| Q2 25 | — | $30.1M | ||
| Q1 25 | — | $28.2M | ||
| Q4 24 | $-11.5M | $30.3M | ||
| Q3 24 | $-14.9M | $30.3M | ||
| Q2 24 | — | $29.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 40.1% | ||
| Q3 25 | 11.5% | 43.1% | ||
| Q2 25 | — | 35.2% | ||
| Q1 25 | — | 36.4% | ||
| Q4 24 | 17.0% | 38.6% | ||
| Q3 24 | -32.9% | 39.3% | ||
| Q2 24 | — | 40.4% |
| Q1 26 | — | 33.4% | ||
| Q4 25 | — | 34.1% | ||
| Q3 25 | 6.8% | 32.1% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 27.4% | ||
| Q4 24 | -25.5% | 34.3% | ||
| Q3 24 | -38.8% | 29.8% | ||
| Q2 24 | — | 29.9% |
| Q1 26 | — | $0.83 | ||
| Q4 25 | — | $0.77 | ||
| Q3 25 | $0.10 | $0.82 | ||
| Q2 25 | — | $0.66 | ||
| Q1 25 | — | $0.64 | ||
| Q4 24 | $-1.13 | $0.68 | ||
| Q3 24 | $-1.47 | $0.69 | ||
| Q2 24 | — | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $198.4M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $1.3B |
| Total Assets | $327.5M | $9.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $198.4M | ||
| Q4 25 | — | $149.1M | ||
| Q3 25 | $195.2M | $259.0M | ||
| Q2 25 | — | $218.3M | ||
| Q1 25 | — | $421.3M | ||
| Q4 24 | $191.5M | $563.1M | ||
| Q3 24 | — | $452.6M | ||
| Q2 24 | — | $730.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $-239.5M | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $-251.7M | $1.1B | ||
| Q3 24 | $-242.9M | $1.1B | ||
| Q2 24 | — | $1.0B |
| Q1 26 | — | $9.9B | ||
| Q4 25 | — | $9.7B | ||
| Q3 25 | $327.5M | $9.8B | ||
| Q2 25 | — | $9.7B | ||
| Q1 25 | — | $9.6B | ||
| Q4 24 | $302.1M | $9.5B | ||
| Q3 24 | — | $9.4B | ||
| Q2 24 | — | $9.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $140.3M | ||
| Q3 25 | $13.8M | $38.3M | ||
| Q2 25 | — | $16.3M | ||
| Q1 25 | — | $27.1M | ||
| Q4 24 | — | $175.2M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $40.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $136.3M | ||
| Q3 25 | $6.5M | $38.0M | ||
| Q2 25 | — | $15.2M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $171.2M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $39.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 116.5% | ||
| Q3 25 | 7.7% | 32.8% | ||
| Q2 25 | — | 13.7% | ||
| Q1 25 | — | 24.3% | ||
| Q4 24 | — | 163.5% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | — | 39.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | 8.8% | 0.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.06× | ||
| Q3 25 | 2.42× | 1.03× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 5.78× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
BY
Segment breakdown not available.
